- Aclarion, Inc. entered into a Securities Purchase Agreement on **October 13, 2025**, for a registered direct offering expected to close on or about **October 14, 2025**.  **[1635077_0001683168-25-007516_acon_ex1001.htm:0]** **[1635077_0001683168-25-007516_aclarion_8k.htm:1]** 
- The offering includes the sale of **64,000 shares** of common stock at **$8.36 per share** and pre-funded warrants to purchase up to **236,000 shares** of common stock with an exercise price of **$0.00001**.  **[1635077_0001683168-25-007516_aclarion_8k.htm:1]** 
- The aggregate gross proceeds from the offering are expected to be approximately **$2.5 million**, before deducting placement agent fees of **7.0%** and other estimated offering expenses.  **[1635077_0001683168-25-007516_aclarion_8k.htm:1]** 
- The net proceeds will be used to fund market development and clinical evidence, The Clarity Trial, product development and quality, general and administration support, and other general corporate purposes.  **[1635077_0001683168-25-007516_aclarion_8k.htm:1]** 
- The company has agreed to a **60-day restriction** on issuing additional common stock or equivalents after the closing date, subject to certain conditions.  **[1635077_0001683168-25-007516_acon_ex1001.htm:30]**

Aclarion (ACON)